Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial

This is a phase II dose escalation trial of carfilzomib in combination with thalidomide and dexamethasone for induction and consolidation in transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). The results of four dose levels are reported. Induction therapy consisted of four cy...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Haematologica
Main Authors: Wester, Ruth, van der Holt, Bronno, Asselbergs, Emelie, Zweegman, Sonja, Kersten, Marie Jose, Vellenga, Edo, van Marwijk Kooy, Marinus, de Weerdt, Okke, Minnema, Monique, Lonergan, Sarah, Palumbo, Antonio, Lokhorst, Henk, Broijl, Annemiek, Sonneveld, Pieter
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6821616/
https://ncbi.nlm.nih.gov/pubmed/30948492
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.205476
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados